FAMILIAL COMBINED HYPERLIPIDEMIA: CURRENT KNOWLEDGE, PERSPECTIVES, AND CONTROVERSIES.
Bello-Chavolla OY, Kuri-García A, Ríos-Ríos M, Vargas-Vázquez A, Cortés-Arroyo JE, Tapia-González G, Cruz-Bautista I, Aguilar-Salinas CA.
Rev Invest Clin. 2018;70(5):224-236. doi: 10.24875/RIC.18002575.
A novel mouse model of familial combined hyperlipidemia and atherosclerosis.
Chen MJ, Xu YT, Sun L, Wang ZH, Little PJ, Wang L, Xian XD, Weng JP, Xu SW.
Acta Pharmacol Sin. 2024 Jun;45(6):1316-1320. doi: 10.1038/s41401-024-01241-8. Epub 2024 Mar 8.
Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia.
Trinder M, Vikulova D, Pimstone S, Mancini GBJ, Brunham LR.
Atherosclerosis. 2022 Jan;340:35-43. doi: 10.1016/j.atherosclerosis.2021.11.032. Epub 2021 Dec 6.
Familial combined hyperlipidaemia/polygenic mixed hyperlipidaemia.
Pedro-Botet J, Climent E, Gabarró N, Millán J.
Clin Investig Arterioscler. 2021 May;33 Suppl 2:43-49. doi: 10.1016/j.arteri.2020.12.013.
Familial combined hyperlipidemia is a polygenic trait.
Gill PK, Hegele RA.
Curr Opin Lipidol. 2022 Apr 1;33(2):126-132. doi: 10.1097/MOL.0000000000000796.
Genetics of Familial Combined Hyperlipidemia (FCHL) Disorder: An Update.
Taghizadeh E, Farahani N, Mardani R, Taheri F, Taghizadeh H, Gheibihayat SM.
Biochem Genet. 2022 Apr;60(2):453-481. doi: 10.1007/s10528-021-10130-2. Epub 2021 Sep 3.
Familial combined hyperlipidemia: An overview of the underlying molecular mechanisms and therapeutic strategies.
Taghizadeh E, Esfehani RJ, Sahebkar A, Parizadeh SM, Rostami D, Mirinezhad M, Poursheikhani A, Mobarhan MG, Pasdar A.
IUBMB Life. 2019 Sep;71(9):1221-1229. doi: 10.1002/iub.2073. Epub 2019 Jul 4.
Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A review.
Taghizadeh E, Mardani R, Rostami D, Taghizadeh H, Bazireh H, Hayat SMG.
J Cell Biochem. 2019 Jun;120(6):8891-8898. doi: 10.1002/jcb.28311. Epub 2018 Dec 16.
Familial Hypercholesterolemia, Familial Combined Hyperlipidemia, and Elevated Lipoprotein(a) in Patients With Premature Coronary Artery Disease.
Vikulova DN, Trinder M, Mancini GBJ, Pimstone SN, Brunham LR.
Can J Cardiol. 2021 Nov;37(11):1733-1742. doi: 10.1016/j.cjca.2021.08.012. Epub 2021 Aug 26.
Combined hyperlipidemia: familial but not (usually) monogenic.
Brahm AJ, Hegele RA.
Curr Opin Lipidol. 2016 Apr;27(2):131-40. doi: 10.1097/MOL.0000000000000270.
